Cargando…
Autoimmune pancreatitis: What we know so far
Autoimmune pancreatitis (AIP) is a rare, often‐missed disease that involves inflammation of the pancreas and strictures of the pancreatic duct. Its prevalence and incidence in the United States remain scarce. The disease has a varied presentation and often mimics pancreatic malignancy, which can mak...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762623/ https://www.ncbi.nlm.nih.gov/pubmed/35071782 http://dx.doi.org/10.1002/jgh3.12688 |
_version_ | 1784633800711471104 |
---|---|
author | Masood, Muaaz |
author_facet | Masood, Muaaz |
author_sort | Masood, Muaaz |
collection | PubMed |
description | Autoimmune pancreatitis (AIP) is a rare, often‐missed disease that involves inflammation of the pancreas and strictures of the pancreatic duct. Its prevalence and incidence in the United States remain scarce. The disease has a varied presentation and often mimics pancreatic malignancy, which can make the diagnosis challenging. Most patients have an excellent response to corticosteroid therapy. Immunomodulators may be used in some cases. Rituximab is an effective, emerging treatment in steroid‐refractory cases. This study aims to review the two distinct types of AIP and provide a detailed analysis of the diagnostic approach and treatment modalities. |
format | Online Article Text |
id | pubmed-8762623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wiley Publishing Asia Pty Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-87626232022-01-21 Autoimmune pancreatitis: What we know so far Masood, Muaaz JGH Open Review Article Autoimmune pancreatitis (AIP) is a rare, often‐missed disease that involves inflammation of the pancreas and strictures of the pancreatic duct. Its prevalence and incidence in the United States remain scarce. The disease has a varied presentation and often mimics pancreatic malignancy, which can make the diagnosis challenging. Most patients have an excellent response to corticosteroid therapy. Immunomodulators may be used in some cases. Rituximab is an effective, emerging treatment in steroid‐refractory cases. This study aims to review the two distinct types of AIP and provide a detailed analysis of the diagnostic approach and treatment modalities. Wiley Publishing Asia Pty Ltd 2021-12-10 /pmc/articles/PMC8762623/ /pubmed/35071782 http://dx.doi.org/10.1002/jgh3.12688 Text en © 2021 The Author. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Masood, Muaaz Autoimmune pancreatitis: What we know so far |
title | Autoimmune pancreatitis: What we know so far |
title_full | Autoimmune pancreatitis: What we know so far |
title_fullStr | Autoimmune pancreatitis: What we know so far |
title_full_unstemmed | Autoimmune pancreatitis: What we know so far |
title_short | Autoimmune pancreatitis: What we know so far |
title_sort | autoimmune pancreatitis: what we know so far |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762623/ https://www.ncbi.nlm.nih.gov/pubmed/35071782 http://dx.doi.org/10.1002/jgh3.12688 |
work_keys_str_mv | AT masoodmuaaz autoimmunepancreatitiswhatweknowsofar |